Dr. Bill Frist, a former U.S. Senate Majority Leader and transplant surgeon, reflects on the transformational impact of generative AI (GenAI) in healthcare. While healthcare has historically struggled with unstructured data and fragmented systems, GenAI offers a breakthrough. Frist identifies key areas of immediate impact and long-term promise. He also cautions about adoption barriers—trust, infrastructure, and change management—but believes GenAI could usher in the most humane, efficient era of medicine yet.
Author: Abhay Panchal
Eli Lilly’s Oral GLP-1 Drug Orforglipron Shows Strong Results in Phase 3 Trial Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, met key endpoints in its Phase 3 ACHIEVE-1 trial for adults with type 2 diabetes. Unlike injectable GLP-1 drugs, orforglipron is a once-daily pill with no food or water restrictions. Key Highlights:
Atmo Biosciences has taken a major step toward commercializing its ingestible gas-sensing capsule after RMIT University officially transferred all intellectual property and patents to the company in exchange for equity. The device, initially developed at RMIT, offers real-time insight into gut health by detecting gaseous biomarkers inside the gastrointestinal tract. Key Highlights:
Apple is developing an AI-powered health coach under “Project Mulberry,” evolving from its earlier “Project Quartz.” The system will use Health app data and doctor-trained AI to deliver personalized health recommendations and video explainers. It will also include advanced food tracking, directly challenging platforms like Noom and MyFitnessPal. The launch is expected with iOS 19.4.
This white paper by EndoSound provides a practical roadmap for integrating Endoscopic Ultrasound (EUS) into Ambulatory Surgery Centers (ASCs), traditionally limited by cost and complexity. Leveraging the EndoSound Vision System™ (EVS™), ASCs can now implement EUS affordably, converting existing endoscopes into EUS-capable devices at a fraction of the cost. The paper outlines key areas for success including financial modeling, equipment needs, staff training, billing strategies, and operational workflows.
Continuing with Esophageal Cancer awareness month, Dr. Parikh interviews Dr. Lishan Aklog, who is chairman and CEO of Lucid Diagnostics. They discuss esophageal cancer pathophysiology, prevalence and the current state of esophageal cancer screening. They then shift their focus to EsoGuard, a novel screening tool for Barrett’s esophagus and esophageal cancer.
Surgery for ulcerative colitis (UC) is often curative for colorectal disease and significantly improves quality of life, especially in patients with medically refractory disease. Dr. Stefan Holubar emphasizes that surgery should not be seen as a last resort but as a viable treatment complementing medical therapy. The most common surgical approach is the three-stage J-pouch procedure, allowing patients to eventually defecate normally without an ostomy. This process includes a colectomy, pouch construction with protective ileostomy, and ileostomy closure.
New treatments for stage 4 colorectal cancer are significantly improving outcomes. While the liver is the most common site of metastasis, therapies like hepatic artery infusion (HAI) deliver highly concentrated chemotherapy directly to the liver, reducing side effects and extending survival by up to 2 years. Additionally, liver transplants are now an option for select patients. Targeted therapies and immunotherapies, especially for those with genetic mutations like Lynch syndrome, are expanding hope.
A new study published in JAMA reveals that despite eligibility, lung cancer screening (LCS) is dramatically underutilized compared to breast (BCS) and colorectal cancer screening (CCS). Among dual-eligible individuals, only about 17% underwent LCS, while more than 64% completed BCS or CCS.
Biotech leaders Guardant Health, Natera, and Exact Sciences are driving a major shift in cancer care through minimal residual disease (MRD) blood tests, which detect trace tumor DNA months before imaging can. These ultrasensitive tests not only identify relapse earlier but also help personalize post-surgical treatment and avoid unnecessary chemotherapy. With a projected market size of $6.7B by 2030, MRD testing is reshaping surveillance, particularly for colorectal, breast, and lung cancers. Though adoption faces hurdles—such as profitability and tissue access—this tech is set to redefine how oncology tracks and treats residual disease.